Burkitt's lymphoma medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 8: Line 8:
The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive [[immunotherapy]] and [[stem cell transplantation]] may be required.<ref Name= Cancer.ca>Burkitt lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/burkitt-lymphoma/?region=on Accessed on September 28, 2015</ref>
The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive [[immunotherapy]] and [[stem cell transplantation]] may be required.<ref Name= Cancer.ca>Burkitt lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/burkitt-lymphoma/?region=on Accessed on September 28, 2015</ref>
===Chemotherapy===
===Chemotherapy===
* Chemotherapeutic regimens for Burkitt's lymphoma include:  
* Chemotherapeutic regimens for Burkitt's lymphoma include:<ref name="JacobsonLaCasce2014">{{cite journal|last1=Jacobson|first1=C.|last2=LaCasce|first2=A.|title=How I treat Burkitt lymphoma in adults|journal=Blood|volume=124|issue=19|year=2014|pages=2913–2920|issn=0006-4971|doi=10.1182/blood-2014-06-538504}}</ref>
* [[Cyclophosphamide]] {{and}} [[Vincristine]] {{and}} [[Doxorubicin]] {{and}} [[Methotrexate]] (CODOX-M)<ref name="pmid29741758">{{cite journal| author=Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K et al.| title=Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. | journal=Br J Haematol | year= 2018 | volume= 181 | issue= 6 | pages= 782-790 | pmid=29741758 | doi=10.1111/bjh.15262 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29741758  }} </ref>
* [[Cyclophosphamide]] {{and}} [[Vincristine]] {{and}} [[Doxorubicin]] {{and}} [[Methotrexate]] (CODOX-M)<ref name="pmid29741758">{{cite journal| author=Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K et al.| title=Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. | journal=Br J Haematol | year= 2018 | volume= 181 | issue= 6 | pages= 782-790 | pmid=29741758 | doi=10.1111/bjh.15262 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29741758  }} </ref>
* [[Ifosfamide]] {{and}} [[Mesna]] {{and}} [[Etoposide]] {{and}} [[Cytarabine]] (IVAC)
* [[Ifosfamide]] {{and}} [[Mesna]] {{and}} [[Etoposide]] {{and}} [[Cytarabine]] (IVAC)
* [[Cyclophosphamide]] {{and}} [[Vincristine]] {{and}} [[Doxorubicin]] {{and}} [[Dexamethasone]] {{and}} [[Methotrexate]] {{and}} [[Cytarabine]] (Hyper-CVAD)
* [[Cyclophosphamide]] {{and}} [[Vincristine]] {{and}} [[Doxorubicin]] {{and}} [[Dexamethasone]] {{and}} [[Methotrexate]] {{and}} [[Cytarabine]] (Hyper-CVAD)
Line 16: Line 16:
* CNS prophylaxis may involve giving [[intrathecal]] chemotherapy, high doses of systemic therapy, or both methods may be used  
* CNS prophylaxis may involve giving [[intrathecal]] chemotherapy, high doses of systemic therapy, or both methods may be used  
* [[Methotrexate]] and [[Cytarabine]] are the drugs used most often for CNS prophylaxis
* [[Methotrexate]] and [[Cytarabine]] are the drugs used most often for CNS prophylaxis
===Biological therapy===
===Biological therapy===
* [[Monoclonal antibodies]] are a type of biological therapy that is effective in treating Burkitt's lymphoma
* [[Monoclonal antibodies]] are a type of biological therapy that is effective in treating Burkitt's lymphoma
* [[Rituximab]] may be added to each of the above chemotherapy regimens
* [[Rituximab]] may be added to each of the above chemotherapy regimens<ref name="JacobsonLaCasce2014">{{cite journal|last1=Jacobson|first1=C.|last2=LaCasce|first2=A.|title=How I treat Burkitt lymphoma in adults|journal=Blood|volume=124|issue=19|year=2014|pages=2913–2920|issn=0006-4971|doi=10.1182/blood-2014-06-538504}}</ref>
===Stem cell transplant===
===Stem cell transplant===
* A [[stem cell transplant]] may be offered to patients with recurrent Burkitt's lymphoma or  to patients who relapse after the treatment.
* A [[stem cell transplant]] may be offered to patients with recurrent Burkitt's lymphoma or  to patients who relapse after the treatment.<ref name="JacobsonLaCasce2014">{{cite journal|last1=Jacobson|first1=C.|last2=LaCasce|first2=A.|title=How I treat Burkitt lymphoma in adults|journal=Blood|volume=124|issue=19|year=2014|pages=2913–2920|issn=0006-4971|doi=10.1182/blood-2014-06-538504}}</ref>
 


==References==
==References==

Revision as of 21:31, 8 January 2019

Burkitt's lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Burkitt's lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study Of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray Findings

CT

MRI

Biopsy

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Burkitt's lymphoma medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Burkitt's lymphoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Burkitt's lymphoma medical therapy

CDC on Burkitt's lymphoma medical therapy

Burkitt's lymphoma medical therapy in the news

Blogs on Burkitt's lymphoma medical therapy

Directions to Hospitals Treating Burkitt's lymphoma

Risk calculators and risk factors for Burkitt's lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Overview

The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive immunotherapy and stem cell transplantation may be required.

Medical Therapy

The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive immunotherapy and stem cell transplantation may be required.[1]

Chemotherapy

  • Chemotherapeutic regimens for Burkitt's lymphoma include:[2]
* Cyclophosphamide AND Vincristine AND Doxorubicin AND Methotrexate (CODOX-M)[3]

CNS prophylaxis

  • There is a high risk that Burkitt's lymphoma will spread to the central nervous system (CNS)
  • CNS prophylaxis may involve giving intrathecal chemotherapy, high doses of systemic therapy, or both methods may be used
  • Methotrexate and Cytarabine are the drugs used most often for CNS prophylaxis

Biological therapy

  • Monoclonal antibodies are a type of biological therapy that is effective in treating Burkitt's lymphoma
  • Rituximab may be added to each of the above chemotherapy regimens[2]

Stem cell transplant

  • A stem cell transplant may be offered to patients with recurrent Burkitt's lymphoma or to patients who relapse after the treatment.[2]


References

  1. Burkitt lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/burkitt-lymphoma/?region=on Accessed on September 28, 2015
  2. 2.0 2.1 2.2 Jacobson, C.; LaCasce, A. (2014). "How I treat Burkitt lymphoma in adults". Blood. 124 (19): 2913–2920. doi:10.1182/blood-2014-06-538504. ISSN 0006-4971.
  3. Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K; et al. (2018). "Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab". Br J Haematol. 181 (6): 782–790. doi:10.1111/bjh.15262. PMID 29741758.

Template:Chromosomal abnormalities


Template:WikiDoc Sources